[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1071325A4 - COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN - Google Patents

COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN

Info

Publication number
EP1071325A4
EP1071325A4 EP99913979A EP99913979A EP1071325A4 EP 1071325 A4 EP1071325 A4 EP 1071325A4 EP 99913979 A EP99913979 A EP 99913979A EP 99913979 A EP99913979 A EP 99913979A EP 1071325 A4 EP1071325 A4 EP 1071325A4
Authority
EP
European Patent Office
Prior art keywords
antigen
compositions
methods
specific vaccination
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99913979A
Other languages
German (de)
French (fr)
Other versions
EP1071325A1 (en
Inventor
Charles A Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1071325A1 publication Critical patent/EP1071325A1/en
Publication of EP1071325A4 publication Critical patent/EP1071325A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • A61K40/4273Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • A61K2039/55533IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99913979A 1998-03-20 1999-03-19 COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN Withdrawn EP1071325A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7889098P 1998-03-20 1998-03-20
US78890P 1998-03-20
PCT/US1999/006034 WO1999046988A1 (en) 1998-03-20 1999-03-19 Compositions and methods for antigen-specific vaccination

Publications (2)

Publication Number Publication Date
EP1071325A1 EP1071325A1 (en) 2001-01-31
EP1071325A4 true EP1071325A4 (en) 2004-12-22

Family

ID=22146831

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99913979A Withdrawn EP1071325A4 (en) 1998-03-20 1999-03-19 COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN

Country Status (5)

Country Link
EP (1) EP1071325A4 (en)
JP (1) JP2002506794A (en)
AU (1) AU759765B2 (en)
CA (1) CA2323232A1 (en)
WO (1) WO1999046988A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
EP1808180A3 (en) * 1999-10-22 2010-12-22 Sanofi Pasteur Limited Modified GP 100 and uses thereof
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MORTARINI R ET AL: "Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.", CANCER RESEARCH. 15 DEC 1997, vol. 57, no. 24, 15 December 1997 (1997-12-15), pages 5534 - 5541, XP002302193, ISSN: 0008-5472 *
NESTLE F O ET AL: "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, March 1998 (1998-03-01), pages 328 - 332, XP002122868, ISSN: 1078-8956 *
REEVES M E ET AL: "RETROVIRAL TRANSDUCTION OF HUMAN DENDRITIC CELLS WITH A TUMOR-ASSOCIATED ANTIGEN GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 24, 15 December 1996 (1996-12-15), pages 5672 - 5677, XP002032192, ISSN: 0008-5472 *
ROSENBERG S A ET AL: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.", NATURE MEDICINE. MAR 1998, vol. 4, no. 3, March 1998 (1998-03-01), pages 321 - 327, XP002091661, ISSN: 1078-8956 *
See also references of WO9946988A1 *
SPECHT JENNIFER M ET AL: "Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 1997, pages 1213 - 1221, XP002148420, ISSN: 0022-1007 *
YONGHONG WAN ET AL: "DENDRITIC CELLS TRANSDUCED WITH AN ADENOVIRAL VECTOR ENCODING A MODEL TUMOR-ASSOCIATED ANTIGEN FOR TUMOR VACCINATION", HUMAN GENE THERAPY, XX, XX, vol. 8, no. 11, 20 July 1997 (1997-07-20), pages 1355 - 1363, XP000877349, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
EP1071325A1 (en) 2001-01-31
WO1999046988A1 (en) 1999-09-23
AU3193499A (en) 1999-10-11
AU759765B2 (en) 2003-05-01
JP2002506794A (en) 2002-03-05
CA2323232A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
CY2020003I1 (en) ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES FOR THE THERAPEUTIC TREATMENT OF CROHN'S DISEASE
FI972945A (en) Compositions suitable for the administration of antigens
ITMI20011986A0 (en) METHOD AND COMPOSITION FOR THE ACTIVATION OF ANTIGEN PRESENTING CELLS
ATE553129T1 (en) ANTIBODIES TO HUMAN IL-12
LU91437I2 (en) "dabigatran-etexilate and its salts - particularly dabigatran-etexilate-mesilate (PRADAXA)"
FR12C0004I2 (en) ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE
EE9700313A (en) Stable reagents for the preparation of radiopharmaceuticals
EE200000470A (en) Human anti-CD40 antibodies
NO20001104D0 (en) Humanized antibodies to human gp39, compositions containing such, and therapeutic uses thereof
ID27408A (en) ABSORPTION OBJECTS AND THE PROCESS OF MAKING
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002226984A1 (en) Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
ID28752A (en) SANITATION METHODS AND COMPOSITIONS
ZA985704B (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
EP0934427A4 (en) Rh blood group antigen compositions and methods of use
BR9605855A (en) Detergent composition and dendritic macromolecule
DE59505585D1 (en) Antigens and antibodies for the detection of collagen I
EE200000055A (en) Process for the preparation of cyclopropylacetylene
EP1071325A4 (en) COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN
EP1032583A4 (en) Active immunization against angiotens
IL137836A0 (en) Methods and compositions for diagnosis of hepatoma
EP1303594A4 (en) GLYCOSYLATED VEGF-B AND METHOD FOR INCREASING THE QUANTITY OF SOLUBLE VEGF-B
ITRM940598A0 (en) "REAGENT FOR THE DETERMINATION OF FREE RADICALS"
EP1393746A4 (en) COMPOSITIONS OF HUMAN POLYCLONAL ANTIBODIES
FR2747308B1 (en) ASSOCIATION OF MARGOUSIER, (-) HYDROXYCITRATE AND CERAMIDES AND COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20041109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060530